AstraZeneca raised its sales and profit outlook for the year thanks to strong demand for its cancer drugs and announced a deal to develop an obesity drug that could be given in tablet form rather than as injections.
由於抗癌藥需求強勁，阿斯特捷利康(AstraZeneca)上調了今年的銷售和利潤預期，並宣佈一項協議，將開發一種可以片劑而非注射劑方式給藥的減肥藥。
您已閱讀7%（287字），剩餘93%（3542字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。